

1

Patient's name:

Patient's date of birth (DD / MMM / YYYY):

Patient's phone:

Emergency contact (name):


Emergency contact (phone):



TREATMENT DETAILS

Please complete this section or ask your doctor to do it.

Isatuximab recommended dose of 10 mg/kg and dosing schedule:



by the Ministry of Health in February 2022.





PATIENT CARD

— DEAR PATIENT RECEIVING SARCLISA (ISATUXIMAB) —

- Provide this card to healthcare providers before blood transfusion.
- Keep this card with you at all times and until 6 months after the last dose of isatuximab.
- You can help identify new safety information, by reporting any side effects you may get. If you notice any side effects, talk to your doctor or pharmacist. You can also report side effects to Ministry of Health by using the link: https://sideeffects.health.gov.il Also, side effects could be reported directly to SANOFI on Tel: 09-8633700
- For further information on isatuximab, you can consult the Package Leaflet (PL).

- Please note this patient is receiving treatment with SARCLISA (isatuximab).
- This patient card contains important safety information that you need to be aware of before, during, and after treatment with isatuximab.
- Treatment with isatuximab binds to CD38 on red blood cells (RBCs) and is associated with a Risk of Interference with blood typing (positive indirect Coombs Test), which may persist for approximately 6 months after the last isatuximab infusion.
- To avoid potential problems with RBC transfusion, you should perform blood type and screen tests prior to the first infusion of isatuximab. Phenotyping may be considered as per local practice.
- If treatment with isatuximab has already started and in the event of a planned transfusion, you should notify the blood bank that the patient is receiving isatuximab and its risk of Interference with Indirect Antiglobulin Tests.
- For additional information on isatuximab, please refer to the Summary of Product Characteristics (SmPC).